EGFR and non-small cell lung carcinoma: Between January 2014 and December 2020, 636 patients were diagnosed with EGFR‐mutated stage IIIB–IV NSCLC, out of which 247 received EGFR–TKI as first‐line therapy and met the inclusion criteria.